Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

Amerigen and VIWA to Establish Chinese Generics Joint Venture

  • Amerigen Pharmaceuticals and VIWA Pharmaceutical inked an agreement through which they aim to set up a joint venture to develop and commercialize branded generic drugs for the Chinese market. The firms project that, once approved, resulting products will be manufactured at Amerigen’s Chinese SFDA- and U.S. FDA-approved plant in Suzhou, China. Marketing and sales would be undertaken by either a Chinese affiliate of VIWA, or a third party.

    “Combining Amerigen’s development capabilities, manufacturing assets, and access to products from Western markets with VIWA’s access to APIs and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio,” remarks Jack H. Ye, VIWA’s MD. “This in turn will help accelerate VIWA's strategic thrust into the commercialization of finished pharmaceutical products in China."

    VIWA Pharmaceutical is focused on the development and commercialization of finished pharmaceuticals for the Chinese and international markets. Generics firm Amerigen has a portfolio of generic drugs in development or filed with the FDA and SFDA. The firm specializes in challenging orally delivered products. 

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »